iCoat Medical AB is a pharmaceutical company based in Stockholm that specializes in clinical research aimed at reducing and preventing ischemia-reperfusion injuries. This condition is particularly relevant in the context of organ transplantation, where it can significantly impact patient outcomes. The company is actively engaged in ongoing research and development efforts to explore innovative approaches that minimize ischemic-reperfusion damage, particularly in kidney transplantation.
The work of iCoat Medical AB has been recognized in the academic community, with preclinical studies published in the American Journal of Transplantation. Co-founder Yuji Teramura has received accolades for his contributions to the field, including a 2025 prize from the Japan Society for Organ Preservation and Biomedical Sciences. The company is dedicated to advancing medical science and improving patient care through the development of innovative therapies that address critical challenges in organ transplantation.